* Citius Pharmaceuticals Inc is expected to show no change in quarterly revenue when it reports results on December 13 (estimated). * * Refinitiv's mean analyst estimate for Citius Pharmaceuticals Inc is for a loss of 4 cents per share. * The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." * The mean earnings estimate of analysts was unchanged in the last three months. * Wall Street's median 12-month price target for Citius Pharmaceuticals Inc is $8, above its last closing price of $1.13. Previous quarterly performance (using preferred earnings measure in US dollars). QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI ENDING ARTESTIMAT IBES MET, SE % E® ESTIMATE MISSED Jun. 30 2022 -0.05 -0.05 -0.06 Missed -20 Mar. 31 2022 -0.07 -0.07 -0.05 Beat 28.6 Dec. 31 2021 -0.06 -0.06 -0.06 Met 0 Sep. 30 2021 -0.04 -0.04 -0.02 Beat 50 Jun. -0.06 -0.06 -0.06 Met 7.7 30 2021 Mar. 31 2021 -0.08 -0.07 -0.04 Beat 46.7 Dec. 31 2020 0.16 0.16 -0.15 Missed -193.7 Sep. 30 2020 -0.11 -0.10 -0.07 Beat 33.3 This summary was machine generated December 9 at 11:19 GMT. All figures in US dollars unless otherwise stated.
